Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

259 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Unusual Case of Superior Vena Cava Syndrome Caused by Intravascular Thyroid Metastasis.
Varela Pose V, Fierro Alanis MP, Bermudez Naveira A, Silva Gonzalez OL, Fernandez Noya J, Anido Herranz U, Lopez Lopez R. Varela Pose V, et al. Among authors: lopez lopez r. Case Rep Oncol Med. 2017;2017:8675239. doi: 10.1155/2017/8675239. Epub 2017 Sep 6. Case Rep Oncol Med. 2017. PMID: 29038739 Free PMC article.
[Gum tumor in a patient with background of hepatic cirrhosis].
García-González J, López Rodríguez R, Abdulkader Nallib I, Anido Herranz U, Vidal Insua Y, López López R. García-González J, et al. Among authors: lopez rodriguez r, lopez lopez r. Rev Clin Esp. 2007 Jul-Aug;207(7):365-6. doi: 10.1157/13107950. Rev Clin Esp. 2007. PMID: 17662203 Spanish. No abstract available.
Brain metastases from prostate adenocarcinoma.
Castro Gómez JE, Anido Herranz U, Carballo Castro A, Gómez Caamaóo A, León Mateos LA, Porto Vázquez C, López López R. Castro Gómez JE, et al. Among authors: lopez lopez r. Clin Transl Oncol. 2009 Jan;11(1):63-4. doi: 10.1007/s12094-009-0313-2. Clin Transl Oncol. 2009. PMID: 19155207
Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study.
Ruiz-Bañobre J, Molina-Díaz A, Fernández-Calvo O, Fernández-Núñez N, Medina-Colmenero A, Santomé L, Lázaro-Quintela M, Mateos-González M, García-Cid N, López-López R, Vázquez S, Anido-Herranz U. Ruiz-Bañobre J, et al. Among authors: lopez lopez r. ESMO Open. 2021 Apr;6(2):100090. doi: 10.1016/j.esmoop.2021.100090. Epub 2021 Mar 16. ESMO Open. 2021. PMID: 33740735 Free PMC article.
Clinical, molecular, and immune correlates of the Immunotherapy Response Score in patients with advanced urothelial carcinoma under atezolizumab monotherapy: analysis of the phase II IMvigor210 trial.
Ferreiro-Pantín M, Anido-Herranz U, Betancor YZ, Cebey-López V, León-Mateos L, García-González J, García-Acuña SM, Fernández-Díaz N, Tubio JMC, López-López R, Ruiz-Bañobre J. Ferreiro-Pantín M, et al. Among authors: lopez lopez r. ESMO Open. 2023 Aug;8(4):101611. doi: 10.1016/j.esmoop.2023.101611. Epub 2023 Jul 27. ESMO Open. 2023. PMID: 37516059 Free PMC article. Clinical Trial.
A three-gene expression score for predicting clinical benefit to anti-PD-1 blockade in advanced renal cell carcinoma.
Betancor YZ, Ferreiro-Pantín M, Anido-Herranz U, Fuentes-Losada M, León-Mateos L, García-Acuña SM, Vaamonde-Rodríguez V, García-Pinel B, Cebey-López V, Villaverde-Viaño R, Lombardía-Rodríguez H, Kotrulev M, Fernández-Díaz N, Gomez-Tourino I, Fernández-Baltar C, García-González J, Tubio JMC, López-López R, Ruiz-Bañobre J. Betancor YZ, et al. Among authors: lopez lopez r. Front Immunol. 2024 Apr 10;15:1374728. doi: 10.3389/fimmu.2024.1374728. eCollection 2024. Front Immunol. 2024. PMID: 38660294 Free PMC article.
A Novel Saliva-Based miRNA Signature for Colorectal Cancer Diagnosis.
Rapado-González Ó, Majem B, Álvarez-Castro A, Díaz-Peña R, Abalo A, Suárez-Cabrera L, Gil-Moreno A, Santamaría A, López-López R, Muinelo-Romay L, Suarez-Cunqueiro MM. Rapado-González Ó, et al. Among authors: lopez lopez r. J Clin Med. 2019 Nov 20;8(12):2029. doi: 10.3390/jcm8122029. J Clin Med. 2019. PMID: 31757017 Free PMC article.
Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.
Borrero-Palacios A, Cebrián A, Gómez Del Pulgar MT, García-Carbonero R, Garcia-Alfonso P, Aranda E, Elez E, López-López R, Cervantes A, Valladares M, Nadal C, Viéitez JM, Guillén-Ponce C, Rodríguez J, Hernández I, García JL, Vega-Bravo R, Puime-Otin A, Martínez-Useros J, Del Puerto-Nevado L, Rincón R, Rodríguez-Remírez M, Rojo F, García-Foncillas J. Borrero-Palacios A, et al. Among authors: lopez lopez r. Sci Rep. 2019 Feb 22;9(1):2589. doi: 10.1038/s41598-019-39291-2. Sci Rep. 2019. PMID: 30796344 Free PMC article. Clinical Trial.
Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.
Borrero-Palacios A, Cebrián A, Gómez Del Pulgar MT, García-Carbonero R, Garcia-Alfonso P, Aranda E, Elez E, López-López R, Cervantes A, Valladares M, Nadal C, Viéitez JM, Guillén-Ponce C, Rodríguez J, Hernández I, García JL, Vega-Bravo R, Puime-Otin A, Martínez-Useros J, Del Puerto-Nevado L, Rincón R, Rodríguez-Remírez M, Rojo F, García-Foncillas J. Borrero-Palacios A, et al. Among authors: lopez lopez r. Sci Rep. 2019 May 17;9(1):7706. doi: 10.1038/s41598-019-43809-z. Sci Rep. 2019. PMID: 31097738 Free PMC article.
259 results